Thrombospondins use the VLDL receptor and a nonapoptotic pathway to inhibit cell division in microvascular endothelial cells

Molecular Biology of the Cell

Volumn 19, Issue 2, 2008, Pages 563-571

  Oganesian, Anush ^a   Armstrong, Lucas C ^c   Migliorini, Mary M ^d   Strickland, Dudley K ^d   Bornstein, Paul ^a,b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c Millipore Corporation   (United States)

^d UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; RECEPTOR PROTEIN; THROMBOSPONDIN 1; THROMBOSPONDIN 2; THYMIDINE; TRITIUM; VASCULOTROPIN; VERY LOW DENSITY LIPOPROTEIN RECEPTOR;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL DEATH; CELL DIVISION; CELL GROWTH; CONTROLLED STUDY; ENDOTHELIUM CELL; FEMALE; HOMEOSTASIS; HUMAN; HUMAN CELL; MITOGENESIS; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SERUM; VASCULAR ENDOTHELIUM;

ANIMALS; APOPTOSIS; CELL DIVISION; CELL PROLIFERATION; CHO CELLS; CRICETINAE; CRICETULUS; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; HUMANS; IMMUNOPRECIPITATION; MICE; MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, LDL; RECOMBINANT PROTEINS; SURFACE PLASMON RESONANCE; THROMBOSPONDIN 1; THROMBOSPONDINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 39449127385     PISSN: 10591524     EISSN: None     Source Type: Journal    
DOI: 10.1091/mbc.E07-07-0649     Document Type: Article

References (54)

1. Adams, J. C. (2001). Thrombospondins: multifunctional regulators of cell interactions. Annu. Rev. Cell Dev. Biol. 17, 25-51.
2. Adams, J. C., and Lawler, J. (2004). The thrombospondins. Int. J. Biochem. Cell Biol. 36, 961-968.
3. Argraves, K. M., Battey, F. D., MacCalman, C. D., McCrae, K. R., Gafvels, M., Kozarsky, K. F., Chappell, D. A., Strauss J. F., 3rd, and Strickland, D. K. (1995). The very low density lipoprotein receptor mediates the cellular catabolism of lipoprotein lipase and urokinase-plasminogen activator inhibitor type I complexes. J. Biol. Chem. 270, 26550-26557.
4. Armstrong, L. C., Björkblom, B., Hankenson, K. D., Siadak, A. W., Stiles, C. E., and Bornstein, P. (2002). Thrombospondin 2 inhibits microvascular endothelial cell proliferation by a caspase-independent mechanism. Mol. Biol. Cell 13, 1893-1905.
5. Armstrong, L. C., and Bornstein, P. (2003). Thrombospondins 1 and 2 function as inhibitors of angiogenesis. Matrix Biol. 22, 63-71.
6. Bornstein, P. (2001). Thrombospondins as matricellular modulators of cell function. J. Clin. Invest. 107, 929-934.
7. Boucher, P., Liu, P., Gotthardt, M., Hiesberger, T., Anderson, R. G., Herz, J. (2002). Platelet-derived growth factor mediates tyrosine phosphorylation of the cytoplasmic domain of the low density lipoprotein receptor-related protein in caveolae. J. Biol. Chem. 277, 15507-15513.
8. Bu, G. (2001). The roles of receptor-associated protein (RAP) as a molecular chaperone for members of the LDL receptor family. Int. Rev. Cytol. 209, 79-116.
9. Dardik, R., Solomon, A., Loscalzo, J., Eskaraev, R., Bialik, A., Goldberg, I., Schiby, G., and Inbal, A. (2003). Novel proangiogenic effect of factor XIII associated with suppression of thrombospondin 1 expression. Arterioscler. Thromb. Vasc. Biol. 23, 1472-14777.
10. Dawson, D. W., Pearce, S.F.A., Zhong, R., Silverstein, R. L., Frazier, W. A., and Bouck, N. P. (1997). CD36 mediates the in vitro inhibitory effects of thrombospondin-1 on endothelial cells. J. Cell Biol. 138, 707-717.
11. de Villiers, W. J. S., Cai, L., Webb, N. R., de Beer, M. C., van der Westhuyzen, D. R., and de Beer, F. C. (2001) CD36 does not play a direct role in HDL or LDL metabolism. J. Lipid Res. 42, 1231-1238.
12. Elzie, C. A., and Murphy-Ullrich, J. E. (2004). The N-terminus of thrombospondin: the domain stands apart. Int. J. Biochem. Cell Biol. 36, 1090-1101.
13. Fischer, J. W., Stoll, M., Hahn, A. W., and Unger, T. (2001). Differential regulation of thrombospondin-1 and fibronectin by angiotensin II receptor subtypes in cultured endothelial cells. Cardiovasc. Res. 51, 784-791.
14. Frykman, P. K., Brown, M. S., Yamamoto, T., Goldstein, J. L., Herz, J. (1995). Normal plasma lipoproteins and fertility in gene-targeted mice homozygous for a disruption in the gene encoding very low density lipoprotein receptor. Proc. Natl. Acad. Sci. USA 92, 8453-8457.
15. Good, D. J., Polverini, P. J., Rastinejad, F., Le Beau, M. M., Lemons, R. S., Frazier, W. A., Bouck, N. P. (1990). A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc. Natl. Acad. Sci. USA 87, 6624-6628.
16. Greenaway, J., Lawler, J., Moorehead, R., Bornstein, P., Lamarre, J., Petrik, J. (2007). Thrombospondin-1 inhibits VEGF levels in the ovary directly by binding and internalization via the low density lipoprotein receptor-related protein-1 (LRP-1). J. Cell Physiol. 210, 807-818.
17. Guo, N., Krutzsch, H. C., Inman, J. K., and Roberts, D. D. (1997). Thrombospondin 1 and type I repeat peptides of thrombospondin 1 specifically induce apoptosis of endothelial cells. Cancer Res. 57, 1735-1742.
18. Gupta, K., Gupta, P., Wild, R., Ramakrishnan, S., and Hebbel, R. P. (1999). Binding and displacement of vascular endothelial growth factor (VEGF) by thrombospondin: effect on human microvascular endothelial cell proliferation and angiogenesis. Angiogenesis 3, 147-158.
19. Heldin, C.-H. and Westermark, B. (1999). Mechanism of action and in vivo role of platelet-derived growth factor. Physiol. Rev. 79, 1283-1316.
20. Herz, J., Goldstein, J. L., Strickland, D. K., Ho, Y. K., and Brown, M. S. (1991). 39-kDa protein modulates binding of ligands to low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor. J. Biol. Chem. 266, 21232-21238.
21. Isenberg, J. S., Ridnour, L. A., Dimitry, J., Frazier, W. A., Wink, D. A., and Roberts, D. D. (2006). CD47 is necessary for inhibition of nitric oxide-stimulated vascular cell responses by thrombospondin-1. J. Biol. Chem. 281, 26069-26080.
22. Jimenez, B., Volpert, O. V., Crawford, S. E., Febbraio, M., Silverstein, R. L., and Bouck, N. (2000). Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1. Nature Med. 6, 41-48.
23. Kellouche, S., Mourah, S., Bonnefoy, A., Schoevaert, D., Podgorniak, M. P., Calvo, F., Hoylaerts, M. F., Legrand, C., and Dosquet, C. (2007). Platelets, thrombospondin-1 and human dermal fibroblasts cooperate for stimulation of endothelial cell tubulogenesis through VEGF and PAI-1 regulation. Exp. Cell Res. 313, 486-499.
24. Kyriakides, T. R., and Bornstein, P. (2003). Matricellular proteins as modulators of wound healing and the foreign body response. Thromb. Haemost. 90, 986-992.
25. Kyriakides, T. R. et al. (1998a). Mice that lack thrombospondin 2 display connective tissue abnormalities that are associated with disordered collagen fibrillogenesis, an increased vascular density, and a bleeding diathesis. J. Cell Biol. 140, 419-430.
26. Kyriakides, T. R., Zhu, Y. H., Yang, Z., and Bornstein, P. (1998b). The distribution of the matricellular protein thrombospondin 2 in tissues of embryonic and adult mice. J. Histochem. Cytochem. 46, 1007-1015.
27. Lampugnani, M. G., Orsenigo, F., Gagliani, M. C., Tacchetti, C., and Dejana, E. (2006). Vascular endothelial cadherin controls VEGFR-2 internalization and signaling from intracellular compartments. J. Cell Biol. 174, 593-604.
28. Lawler, J. (2002). Thrombospondin-1 as an endogenous inhibitor of angiogenesis and tumor growth. J. Cell Mol. Med. 6, 1-12.
29. Lawler, J., and Detmar, M. (2004). Tumor progression: the effects of thrombospondin-1 and -2. Int. J. Biochem. Cell Biol. 36, 1038-1045.
30. Lillis, A. P., Mikhailenko, I., Strickland, D. K. (2005).). Beyond endocytosis: LRP function in cell migration, proliferation and vascular permeability. J. Thromb. Haemost. 3, 1884-1893.
31. Loukinova, E., Ranganathan, S., Kuznetsov, S., Gorlatova, N., Migliorini, M. M., Loukinov, D., Ulery, P. G., Mikhailenko, I., Lawrence, D. A., and Strickland, D. K. (2002). Platelet-derived growth factor (PDGF)-induced tyrosine phosphorylation of the low density lipoprotein receptor-related protein (LRP). Evidence for integrated co-receptor function between LRP and the PDGF J. Biol. Chem. 277, 15499-15506.
32. May, P., Herz, J., and Bock, H. H. (2005). Molecular mechanisms of lipoprotein receptor signalling. Cell Mol. Life Sci. 62, 2325-2338.
33. Mikhailenko, I., Kounnas, M. Z., and Strickland, D. K. (1995). Low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor mediates the cellular internalization and degradation of thrombospondin. A process facilitated by cell-surface proteoglycans. J. Biol. Chem. 270, 9543-9549.
34. Mikhailenko, I., Krylov, D., Argraves, K. M., Roberts, D. D., Liau, G., and Strickland, D. K. (1997). Cellular internalization and degradation of thrombospondin-1 is mediated by the amino-terminal heparin binding domain (HBD). High affinity interaction of dimeric HBD with the low density lipoprotein receptor-related protein. J. Biol. Chem. 272, 6784-6791.
35. Murphy-Ullrich, J. E., and Poczatek, M. (2000). Activation of latent TGF-beta by thromospondin-1, mechanisms and physiology. Cytokine Growth Factor Rev. 11, 59-69.
36. Newton, C. S., Loukinova, E., Mikhailenko, I., Ranganathan, S., Gao, Y., Haudenschild, C., and Strickland, D. K. (2005). Platelet-derived growth factor receptor-beta (PDGFR-beta) activation promotes its association with the low density lipoprotein receptor-related protein (LRP). Evidence for co-receptor function. J. Biol. Chem. 280, 27872-27878.
37. Nor, J. E., Mitra, R. S., Sutorik, M. M., Mooney, D. J., Castle, V. P., and Polverini, P. J. (2000). Thrombospondin-1 induces endothelial cell apoptosis and inhibits angiogenesis by activating the caspase death pathway. J. Vasc. Res. 37, 209-218.
38. Olsson, A.-K., Dimberg, A., Kreuger, J., and Claesson-Welsh, L. (2006). VEGF receptor signalling - in control of vascular function. Nat. Rev. Mol. Cell Biol. 5, 359-371.
39. Pelicci, G., Lanfrancone, L., Grignani, F., McGlade, J., Cavallo, F., Forni, G., Nicoletti, I., Grignani, F., Pawson, T., and Pelicci, P. G. (1992). A novel transforming protein (SHC) with an SH2 domain is implicated in mitogenic signal transduction. Cell 70, 93-104.
40. Rastinejad, F., Polverini, P. J., and Bouck, N. P. (1989). Regulation of the activity of a new inhibitor of angiogenesis by a cancer suppressor gene. Cell 56, 345-355.
41. Ravichandran, K. S. (2001). Signaling via Shc family adapter proteins. Oncogene 20, 6322-6330.
42. Ruiz, J. et al. (2005). The apoE isoform binding properties of the VLDL receptor reveal marked differences from LRP and the LDL receptor. J. Lipid Res. 46, 1721-1731.
43. Salgado, R., Benoy, I., Bogers, J., Weytjens, R., Vermeulen, P., Dirix, L., and Van Marck, E. (2001). Platelets and vascular endothelial growth factor (VEGF): a morphological and functional study. Angiogenesis. 4, 37-43.
44. Schwartz, S. M., and Benditt, E. P. (1973). Cell replication in the aortic endothelium: a new method for study of the problem. Lab. Invest. 28, 699-707.
45. Short, S. M., Derrien, A., Narsimhan, R. P., Lawler, J., Ingber, D. E., and Zetter, B. R. (2005). Inhibition of endothelial cell migration by thrombospondin-1 type-1 repeats is mediated by beta1 integrins. J. Cell Biol. 168, 643-653.
46. Simantov, R., Febbraio, M., and Silverstein, R. L. (2005). The antiangiogenic effect of thrombospondin-2 is mediated by CD36 and modulated by histidine-rich glycoprotein. Matrix Biol. 24, 27-34.
47. Stolt, P. C., and Bock. H. H. (2006). Modulation of lipoprotein receptor functions by intracellular adaptor proteins. Cell Signal. 18, 1560-1571.
48. Strickland, D. K., Ashcom, J. D., Williams, S., Burgess, W. H., Migliorini, M., and Argraves, W. S. (1990). Sequence identity between the alpha 2-macroglobulin receptor and low density lipoprotein receptor-related protein suggests that this molecule is a multifunctional receptor. J. Biol. Chem. 265, 17401-17404.
49. Trommsdorff, M., Gotthardt, M., Hiesberger, T., Shelton, J., Stockinger, W., Nimpf, J., Hammer, R. E., Richardson, J. A., and Herz, J. (1999). Reeler/ Disabled-like disruption of neuronal migration in knockout mice lacking the VLDL receptor and ApoE receptor 2. Cell 97,689 -701.
50. Webb, N. J., Bottomley, M. J., Watson, C. J., and Brenchley, P. E. (1998). Vascular endothelial growth factor (VEGF) is released from platelets during blood clotting: implications for measurement of circulating VEGF levels in clinical disease. Clin. Sci. 94, 395-404.
51. Wyne, K. L., Pathak, K., Seabra, M. C., and Hobbs, H. H. (1996). Expression of the VLDL receptor in endothelial cells. Arterioscler. Thromb. Vasc. Biol. 16, 407-415.
52. Yang, Z., Strickland, D. K., and Bornstein, P. (2001). Extracellular matrix metalloproteinase 2 levels are regulated by the low density lipoprotein-related scavenger receptor and thrombospondin 2. J. Biol. Chem. 276, 8403-8408.
53. Zhang, X., Galardi, E., Duquette, M., Lawler, J., and Parangi, S. (2005). Antiangiogenic treatment with three thrombospondin-1 type 1 repeats versus gemcitabine in an orthotopic human pancreatic cancer model. Clin. Cancer Res. 15, 5622-5630.
54. Zhang, X., and Lawler, J. (2007). Thrombospondin-based antiangiogeneic therapy. Microvasc. Res. Epub ahead of print.